PLPaul Lips

Paul Lips

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Lips has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association analyses of 47,500 individuals identifies six fracture loci and 82 BMD loci clustering in biological pathways that regulate osteoblast and osteoclast activity

    by K. Estrada, E. Evangelou, Y.-H. Hsu, U. Styrkarsdottir, C.-T. Liu, A. Moayyeri, S. Kaptoge, E. Duncan, N. Amin, D. Kiel, et al.


  • Subclinical Thyroid Disorders, Physical and Cognitive Function, and Mortality in Older Individuals.

    by Rt de Jongh, P Lips, Nm van Schoor, Kj Rijs, Dj Deeg, Mh Kramer, Jp Vandenbroucke, Om Dekkers

    Article published by the Endocrine Society Article published by the Endocrine Society

  • What is the optimal level of serum 25-hydroxyvitamin D for bone health in older people? Different thresholds for different outcomes

    by N.O. Kuchuk⁎, S.M.F. Pluijm, N.M. van Schoor, C.W.N. Looman, J.H. Smit, P. Lips

    • 20 July 2002
      • Vol. 146  (29) , 1374-80

    [Comparable case finding percentages of osteoporosis despite diverging reasons for ordering bone densitometry by general practitioners and specialists].

    by E Van Der Poest Clement, J Van Hartskamp, J C Roos, J H De Vries, P Lips

    To assess the use of bone densitometry in practice. Retrospective. General practitioners who had ordered bone densitometry for their patients were asked to fill in a questionnaire on the reasons for the request and the subsequent treatment they prescribed. For a similar number of patients from the outpatient clinics of general internal medicine and endocrinology, the medical records were examined to obtain the same information. In 9 months, general practitioners requested 150 bone density measurements; for 117 of these the data were complete. In one year, 150 measurements were requested by the outpatient clinics. Marked differences in the reasons for the request were seen in loss of body height, back pain and requests from the patient (indications for general practitioners) and in osteoporotic fractures and the use of corticosteroids (indications for specialists). The average result of the measurements, however, was the same, with mean T-scores in the lumbar spine of -2.26 and -2.19, respectively and case-finding percentages of osteoporosis of 21% on the basis of the lumbar spine and 40% on the basis of the spine or hip. Bone densitometry carried out after an osteoporotic fracture was associated with the lowest mean bone mineral density, followed by measurement on the basis of abnormal X-rays. Bone densitometry at the patient's request was associated with the highest bone density. The percentage of patients found to have osteoporosis turned out to be dependent on the site of measurement, the used reference ranges, and the method of reporting, especially for patients older than 70 years. When the bone density corresponded to a diagnosis of osteoporosis, nearly all patients were treated, mainly with a bisphosphonate. Treatment was also frequently started when the bone density was reduced, i.e. in case of osteopenia. Some patients with normal bone density were treated as well. The reason for such treatment was not always clear. General practitioners and specialists used different risk factors in deciding whether bone densitometry was indicated. However, the two groups used this diagnostic tool with equal efficiency, since both the percentages of osteoporosis detected and the average bone densities were the same.

  • Open Access

    A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial

    by Paul Lips, Tu Duong, Anna Oleksik, Dennis Black, Steven Cummings, David Cox, Thomas Nickelsen

    Vitamin D deficiency leads to secondary hyperparathyroidism, increased bone turnover, and bone loss and, when severe, to osteomalacia. Vitamin D deficiency is common in elderly people, especially the institutionalized. The definition of vitamin D deficiency is hampered by the fact that large interlaboratory differences exist in assays for serum 25-hydroxyvitamin D (25OHD), the main circulating metabolite. The international Multiple Outcomes of Raloxifene Evaluation study, a large prospective intervention trial in postmenopausal women with osteoporosis, offered the opportunity to compare vitamin D status and parathyroid function throughout many countries over the world. For this study, baseline data were available from 7564 postmenopausal women from 25 countries on 5 continents. All women had osteoporosis, i.e. bone mineral density (BMD) at femoral neck or lumbar spine was lower than t-score −2.5, or they had 2 vertebral fractures. Serum 25OHD was measured by RIA, and serum PTH was measured by immunoradiometric assay. BMD was measured by dual x-ray absorptiometry. The mean (±sd) serum 25OHD was 70.8± 30.9 nmol/L. A low serum 25OHD (P < 0.001). This significant negative correlation was observed in all regions. When serum 25OHD was less than 25, 25–50, or more than 50 nmol/L, respectively, mean serum PTH levels were 4.8, 4.1, and 3.5 pmol/L, respectively (by ANOVA, P < 0.001). Similarly, mean alkaline phosphatase levels were 83.7, 79.1, and 75.7 U/L (P < 0.001), respectively, with increasing serum 25OHD. The effect of serum 25OHD on BMD was only significant for the BMD of the trochanter where a serum 25OHD level less than 25 nmol/L was associated with a 4% lower BMD. After 6 months of treatment with vitamin D3 (400–600 IU/day) and calcium (500 mg/day), serum 25OHD increased from 70.8 ± 29.8 to 92.3 ± 28.6 nmol/L. Serum PTH decreased significantly after 6 months of treatment, and this decrease depended on baseline serum 25OHD. When baseline serum 25OHD was less than 25, 25–50, or more than 50 nmol/L, respectively, serum PTH decreased by 0.8, 0.5, or 0.2 pmol/L, respectively (P < 0.001). In conclusion, serum 25OHD was less than 25 nmol/L in 4% of the women, and this was associated with a 30% higher serum PTH. In 24% of the women serum 25OHD was between 25–50 nmol/L, associated with a 15% higher level of serum PTH compared with women with a serum 25OHD greater than 50 nmol/L. A low serum 25OHD level was also associated with higher serum alkaline phosphatase and lower BMD of the trochanter. Treatment with vitamin D3 and calcium increased serum 25OHD and decreased serum PTH significantly; the effect was greater for lower baseline serum 25OHD.


  • Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma

    by P Lips, E.F.I Comans, O.S Hoekstra, E van der Poest Clement, J.C van Mourik, G.J.J Teule


  • Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO)

    by P. Lips, C. Cooper, D. Agnusdei, F. Caulin, P. Egger, O. Johnell, J. A. Kanis, S. Kellingray, A. Leplege, U. A. Liberman, et al.

    Vertebral fractures may be minor or lead to pain, decreased physical function, immobility, social isolation and depression, which together contribute to quality of life. A Working Party of the European Foundation for Osteoporosis has developed a specfic questionnaire for patients with vertebral fractures. This questionnaire, QUALEFFO, includes questions in the domains pain, physical function, social function, general health perception and mental function. QUALEFFO was validated in a multicenter study in seven countries. The study was done in 159 patients aged 55–80 years with clinical osteoporosis, i.e., back pain and other complaints with at least one vertebral fracture and lumbar bone mineral density T-score <−1. Patients with a recent vertebral fracture were excluded because of unstable disease. Controls were age- and sex-matched, and did not have chronic back pain or vertebral fractures. Subjects with conditions exerting a major influence on quality of life were excluded. The QUALEFFO was administered twice within 4 weeks and compared with a generic questionnaire, the Short Form 36 of the Medical Outcomes Study (SF-36). Standard spinal radiographs were made for assessment of vertebral height. Seven questions were removed from the analysis because of low response rate, linguistic ambiguities or redundancy. The 41 remaining questions were analyzed for repeatability, internal consistency and the capacity to discriminate between patients with vertebral fractures and controls. Comparison with the SF-36 was performed within similar domains by conditional logistic regression and by receiver operating characteristic (ROC) curves. The repeatability of QUALEFFO was good (kappa statistics 0.54–0.90) and 26 of 41 questions had a kappa score ≥0.70. The internal consistency of the five domains was adequate, with Crohnbach α around 0.80. All except five questions discriminated significantly between patients and controls. The median scores of QUALEFFO were significantly higher in patients with vertebral fractures than in controls in all five domain (p<0.001), which is consistent with decreased quality of life in patients with osteoporosis. Spinal radiographs were assessed using the McCloskey–Kanis algorithm. According to this, 124 patients (78%) had vertebral fractures of ≥3 SD severity, in contrast with 7 controls (4%). Significant correlations existed between scores of similar domains of QUALEFFO and the SF-36, especially for pain, physical function and mental function. All five domains within each questionnaire discriminated significantly between fracture cases and controls. The odds ratios for pain and social function were greater for QUALEFFO, while general health perception was more discriminating using the SF-36. The ROC curve analysis of QUALEFFO indicated that all five domains were significantly predictive of vertebral fractures. When comparing similar domains of the two questionnaires, QUALEFFO domains demonstrated significantly better performance for pain, physical function and social function. The QUALEFFO total score and SF-36 physical composite score showed similar performance. In conclusion, QUALEFFO is repeatable, coherent and discriminates well between patients with vertebral fractures and control subjects. The results of this study confirm the decreased quality of life in patients with vertebral fractures.


  • Prevention of corticosteroid induced osteoporosis

    by Paul Lips

    Corticosteroid induced osteoporosis has presented a challenge to clinicians for many years. Bone loss during corticosteroid treatment is mediated by inhibition of gonadal and adrenal steroid production, leading to hypogonadism and a direct negative effect on calcium absorption and osteoblast function.1 Epidemiological data suggest that corticosteroid treatment doubles the risk of fractures of the hip and distal radius and at least quadruples the risk of vertebral fracture. How can this damage be limited? Corticosteroids are widely used, especially for rheumatoid arthritis, polymyalgia rheumatica, and chronic obstructive pulmonary disease. A cross sectional study in Nottinghamshire in over 65 000 patients showed that 0.5% were taking oral corticosteroids.2 Most were aged 60-80 years and the mean dose was 8 mg/day, with a median duration of treatment of three years. Only 14% of these patients had received preventive treatment for osteoporosis. If these data are extrapolated to the whole population, over 250 000 people in the United Kingdom are taking oral corticosteroids. Monitoring bone loss has become easy now that bone mineral density can be measured with dual energy x ray absorptiometry. Nevertheless, many patients taking long term corticosteroids are not referred for bone mineral density …